Age-related macular degeneration

Journal of the Royal Society of Medicine

Volumn 102, Issue 2, 2009, Pages 56-61

  Ayoub, Tariq ^a   Patel, Nishal ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60049089606     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2009.080298     Document Type: Review

References (49)

1. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 1999;106:1056-65
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51
3. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2
4. Ferris FL, Davis MD, Clemons TE, et al. Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No.18. Arch Ophthalmol 2005;123:1570-4
5. Francis PJ, Schultz DW, Hamon S, Ott J, Weleber RG, Klein ML. Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration. PLoS ONE 2007;2:e1197
6. Gohel PS, Mandava N, Olson JL, Durairaj VD. Age-related macular degeneration: An update on management. Am J Med 2008;121:279-81
7. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-21
8. Baird PN, Richardson AJ, Robman LD, et al. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat 2006;27:337-42
9. Hornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye 2005;19:935-4
10. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
11. Seddon JM, Cote J, Davis N, et al. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003;121:785-92
12. Schaumberg DA, Christen WG, Hunkinson SE, et al. Body mass index and the incidence of visually significant ARMD in men. Arch Ophthalmol 2001;119:1259-65
13. Wachter A, Sun Y, Dasch B, et al. Munster age and retina study (MARS): Association between risk factors for atherosclerosis and age-related macular degeneration. Ophthalmologe 2004;101:50-3
14. Klein R, Klein BE, Tomany SC, et al. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2003;110:636-43
15. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol Med 2004;10:417-20
16. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-63
17. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-31
18. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-89
19. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-24
20. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-68
21. Amin R, Puklin JE, Frank RN. Growth factor localization ain choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:3178-88
22. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36
23. Hughes EH, Khan J, Patel N, Kashani S, Chong NV. In vivo demonstration of the anatomic differences between classic and occult choroidal neovascularization using optical coherence tomography. Am J Ophthalmol 2005;139:344-6
24. Chong E, Wong T, Kreis A, Simpson J, Guymer R. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 2007;335:755
25. Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2006;2:CD000254
26. See http://www.areds2.orrg/
27. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-114
28. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees ret inectomy for neovascular age-related macular degeneration. Ophthalmology 2004;111:1715-24
29. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with vertiporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329-45
30. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207
31. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 2004;24:1-12
32. Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007;3:CD002030
33. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
34. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5
35. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90
36. Freeman WR, Falkenstein I. Avastin and new treatments for AMD: where are we? Retina 2006;26:853-7
37. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
38. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
39. See http://www.nice.org.uk/Guidance/TA155
40. See http://www.rcophth.ac.uk/about/press/#NICEGuidanceWetAMD
41. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676-98
42. See http://www.cabernetstudy.com/
43. Antoszyk AN, Tuomi L, Chung CY, Singh A. FOCUS Study Group. Ranbizumab combined with verteporfin photodynamic therapy in neovascular age-related macular generation (FOCUS): Year 2 results. Am J Ophthalmol 2008;145:862-74
44. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003;44:4989-93
45. Cheng L, Rivero ME, Garcia CR, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 2001;17:295-304
46. Ciulla TA, Criswell MH, Danis RP, Williams JI, McLane MP, Holroyd KJ. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003;23:808-14
47. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alphainterferon. Ophthalmology 1993;100:9-14
48. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007;4:371-88
49. Guidetti B, Azéma J, Malet-Martino M, Martino R. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers. Curr Drug Deliv 2008;5:7-19